- Home
- GLPG vs FCF Comparison
GLPG vs FCF Comparison
Compare GLPG & FCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | FCF |
|---|---|---|
| Founded | 1999 | 1934 |
| Country | Belgium | United States |
| Employees | 704 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | GLPG | FCF |
|---|---|---|
| Price | $29.98 | $17.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $36.50 | $19.75 |
| AVG Volume (30 Days) | 150.8K | ★ 828.5K |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | N/A | ★ 5.76 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.32 |
| Revenue Next Year | N/A | $6.25 |
| P/E Ratio | ★ N/A | $11.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.59 | $13.54 |
| 52 Week High | $37.78 | $19.08 |
Technical Indicators
Market Signals| Indicator | GLPG | FCF |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 56.44 |
| Support Level | $28.78 | $17.21 |
| Resistance Level | $33.67 | $17.83 |
| Average True Range (ATR) | 0.86 | 0.33 |
| MACD | -0.28 | 0.10 |
| Stochastic Oscillator | 30.85 | 93.75 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.